65,437 trials
Metastatic Renal Cell Carcinoma
Primary: Clinical Response - IL-2 Combined With Hydroxychloroquine (HCQ) at Either 1,200 mg/d or 600 mg/d) (All Patients) — 9; 14; 3; 3 Participants
Acute Diverticulitis
Primary: Short-term Morbidity — 8; 1 Participants
Metastatic Colorectal Cancer
Primary: Efficacy Duration of Disease Control by Tumor Assessment (CT/MRI/Clinical Examination) — 373.00; 370.00 days — p=0.967
Plaque Psoriasis
Primary: Percentage of Participants With a Dermatology Life Quality Index 0/1 (DLQI 0/1) Response at Week 16 — 74.7; 71.3; 61.7; 70.8 Percentage of participants
Rhinitis, Allergic, Perennial · House Dust Mite Allergy
Primary: Total Combined Score — 3.62; 4.35 Units on a scale — p=<0.0001
Radial Artery
Primary: Radial Artery Cross Sectional Area — 3.4; 3.0 mm^2
Sub-acute Back Pain
Primary: Number of Participants With 20% Reduction in Pain on the NRS Pain Intensity Scale — 5; 15; 21 Participants — p=1.0
Breast Cancer
Primary: Percent Accuracy of Contrast Mammography — 100; 67 percentage of accuracy
Opioid Use, Unspecified
Primary: Safe Medication Dosing (Prescription Understanding) — 0.67; 0.83; 0.79 probability
Testosterone Deficiency · Hypogonadism, Male
Primary: Change in Levels of Serum Total Testosterone Concentration — NA; 1043.6; NA; 785.7 ng/dl
Coronary Heart Disease
Primary: Myocardial Perfusion — 1.83; 1.52 myocardial perfusion index
Hepatic Impairment · Healthy Volunteers
Primary: Cmax: Maximum Observed Plasma Concentration for TAK-954 (Total and Free) — 2.629; 2.440; 1.893; 0.1381 nanogram per milliliter (ng/mL) — p=0.579
Chronic Hepatitis B
Primary: Percentage of Participants With Hepatitis B Virus (HBV) DNA Levels ≥ 20 IU/mL at Week 48, as Determined by the Modified United States Food and Drug Administration (US…
Adnexal Mass
Primary: Diagnostic Accuracy of Subharmonic Ultrasound Imaging Compared to Standard Ultrasound or Contrast Enhanced Magnetic Resonance Imaging (MRI) — 70; 56 percent accurate…
Leukemia
Primary: Maximum Tolerated Dose (MTD) of Bendamustine Combined With Fixed-Dose Fludarabine and Rituximab (FBR) — 30 mg/m^2